Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
Lim KH, Pardanani A, Butterfield JH, et al.
Blood · 2009
Grade Bcohort
Key Findings
- ●Confirms imatinib ineffective in D816V+ SM
- ●May benefit occasional D816V-negative patients
Referenced in (1 disease)
ID: pmid-19193436DOI: 10.1182/blood-2009-01-199794PMID: 19193436